Navigation Links
Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
Date:2/19/2008

Pamela Harris appointed to lead Diabetes Sales, Managed Care and Government

Accounts on national level

PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Novo Nordisk, a healthcare company with an 85-year history of innovation and achievement in diabetes care, today announced the company has appointed Pamela Harris as vice president for Diabetes Sales, Managed Care and Government Accounts, effective immediately.

Harris, who since 2005 shared responsibility for managing the diabetes field force, will assume an expanded role of leading the company's 2,000-person field organization of representatives and managed market account executives.

"Pam has developed an impressive and successful track record in sales, managed healthcare, training and marketing," said Jerzy Gruhn, president of Novo Nordisk, Inc. "Her leadership style and strong business experience will help us continue to grow our company and help change the lives of millions of people living with diabetes."

Harris joined Novo Nordisk in 2005 after leading one of the national sales teams at Novartis Pharmaceuticals. In her 28 years in the pharmaceutical industry, she has held various positions in sales leadership roles, training, and marketing. Harris has received several awards recognizing her achievements. At Bristol-Myers Squibb, she was recognized for outstanding leadership and selected from 800 nominees worldwide to receive the Bristol-Myers Squibb Leadership Development Award. Additionally, she has been honored by the Harlem YWCA and was the recipient of their Black Achiever in Industry Award.

Harris received a Bachelor's degree from the College of New Jersey (formerly Trenton State College).

About Novo Nordisk

Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products wit
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Novo Nordisk Appoints New Leader of North American Business
2. Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes
3. Novo Nordisk Settles With Pfizer On Patent Infringement Suit
4. Novo Nordisk Increased Net Profit by 32% in 2007
5. Novo Nordisk Files Annual Report with the SEC
6. Adverse housing conditions contribute to diabetes risk
7. RAND finds cases of undiagnosed diabetes drop sharply
8. UCLA researchers identify markers that may predict diabetes in still-healthy people
9. Diabetes appears to increase risk of death for patients with acute coronary syndromes
10. Discovery of sugar sensor in intestine could benefit diabetes
11. Despite overeating, morbidly obese mice gain protection against diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...quick to condemn hurtful comments, study suggests ...- Many people overestimate how strongly they would... , Sixty-three percent of study participants at...er for an experiment with a white person rather th...acist comments about the black person when he left...
(Date:1/8/2009)..., Md., Jan. 8 Hanger Or...announce that throughout the fourth quarter of 200... Center, Rocky Mountain Orthotic-Prosthetics Cente...nc., First Coast Orthotics & Prosthetics, and ...uisitions add patient care centers to existing mar...
(Date:1/8/2009)...ESDA, Md., Jan. 8 /PRNewswire-Asia/ -- Chindex Int...e Company"), a leading independent American,provi... the People,s Republic,of China, today announced ...,China Conference, to be held in Shanghai on Janua...ina Conference will be held at the Pudong Shangri-...
(Date:1/8/2009)...Pa., Jan. 8 Cephalon, I...Baldino, Jr., Ph.D., Chairman and CEO will presen...held on January 13, 2009 in San Francisco, CA at a...n Time). The presentation will be webcast live on ...bsite. , , The webcast will be archived for on...
Breaking Medicine News(10 mins):Health News:Many Turn Blind Eye to Racism 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3
...f the major causes of death among South Africa's y...s said. // Head of Policy Co-ordination and Advis...nzhe said they had conducted research and found th...e in HIV-AIDS-related deaths among young South Afr...
...complex mouth movements like blowing bubbles and l...age quickly, researchers say. // Katie Alcock and...tain studied 120 toddlers and carried out a series...s that might predict a child's ability to develop ...
...t transplants are on the decline. This is because ...y//. Hence the doctors at the Papworth Hospital in...rt was kept beating for five hours after it was re...n to receive a beating heart transplant was Michae...
...y of Adrian Bird, a molecular geneticist at the Un...23rd June// that the abnormally high levels of a p...s models of Rett Syndrome is causing its mitochond...rk overtime. Dr. Bird stated that this is the firs...
Other Medicine News:Health News:Latest In the Heart Transplant Field 2Health News:Researchers Have Linked Rett Syndrome to Mitochondrial Gene 2Health News:Researchers Have Linked Rett Syndrome to Mitochondrial Gene 3
(Date:1/8/2009)...o, Jan. 8 IntelligentMDx a develope...ays, today announced that verification studies of ... complete. , , Under the verification protocol...d reproducibility and robustness of the BK Viral Q... agreed with internally generated analytical perfo...
(Date:1/7/2009)...re-FirstCall/ -- Eli Lilly and Company,(NYSE: L...esponse letter from,the U.S. Food and Drug Admini...on (LAI) for acute and maintenance treatment of sc...k with the agency on the new drug,application (ND...al clinical trials for the continued,review of th...
(Date:1/7/2009)...rease , , WHITE PLAINS, N.Y., Jan. 7 /PRNewswir... that the decades-long rise in the United States p...than ever at increased risk of death and disabilit...43,000 babies were born too soon in 2006, accordin...ich today released "Births: Final data for 2006," ...
(Date:1/7/2009)...opment Based On Osteotech,s Proprietary Human Coll...on; FDA Filing Anticipated in Third Quarter 2009 ...ll/ -- Osteotech, Inc. (Nasdaq: OSTE ), a lead...regenerative healing, announced today that it has ...h(TM) BioRegeneration Matrix. The first five patie...
Breaking Medicine Technology:Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 2Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6Preterm Births Rise 36 Percent Since Early 1980s 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3MINRAD International Inc Announces FDA Approval of Petrem 28TM 29 Sevoflurane 21372 1MINRAD International Inc Announces FDA Approval of Petrem 28TM 29 Sevoflurane 21372 2Congressional Leaders and Mens Health Network Emphasize the Importance of Health During the 15th Annual National Mens Health Week 21370 1Congressional Leaders and Mens Health Network Emphasize the Importance of Health During the 15th Annual National Mens Health Week 21370 2Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 1Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 2Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 3Consumer Reports 3A Patients Overdose on Debt As Lenders Doctors and Hospitals Push Risky Credit to Pay for Medical Care 21368 4Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 1Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 2Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 3Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 4Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 5Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 6Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ 004 28Staccato 28R 29 Loxapine 29 for Acute Agitation 2375 7
...ently approved by FDA for long-term maintenance,tr...ate first,nebulized formoterol fumarate provides i...moterol, enhanced patient quality of,life, and pos...7 /PRNewswire/ -- Data presented at the,Internatio...TS),demonstrate that Perforomist (formoterol fumar...
...ivolol Lowers Blood Pressure in Obese and,Non-Obes...Newswire-FirstCall/ -- Forest,Laboratories, Inc. t...dies and one pooled analysis of nebivolol, a selec...urrently under review by,the U.S. Food and Drug Ad...on. Data from the two clinical studies show that,n...
Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 2Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 3Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 4
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top
Medicine Products: